Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:3015-3015
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Gettinger Scott N.¹,Kowanetz Marcin²,Koeppen Hartmut²,Wistuba Ignacio Ivan³,Kockx Mark⁴,Kadel Edward E.²,Rizvi Naiyer A.⁵,Spira Alexander I.⁶,Hirsch Fred R.⁷,Boyd Zachary²,Denker Mitchell²,Minn Alexandra²,Shames David S.²,Sandler Alan²,Chen Daniel S.²,Hegde Priti S.²,Spigel David R.⁸

Affiliation:

1. Yale School of Medicine, New Haven, CT

2. Genentech, Inc., South San Francisco, CA

3. The University of Texas MD Anderson Cancer Center, Houston, TX

4. Histogenex, Berchem, Belgium

5. Columbia University Medical Center, New York, NY

6. Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, VA

7. University of Colorado Cancer Center, Denver, CO

8. Sarah Cannon Research Institute, Nashville, TN

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.3015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC;Journal of Thoracic Oncology;2018-11

2. Diagnostic value of LunX mRNA and CEA mRNA expression in pleural fluid of patients with non-small cell lung cancer;Minerva Respiratory Medicine;2017-05

3. Prospects and progress of atezolizumab in non-small cell lung cancer;Expert Opinion on Biological Therapy;2017-03-28

4. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project;Journal of Thoracic Oncology;2017-02

5. Elements of cancer immunity and the cancer–immune set point;Nature;2017-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3